UPDATE: Jefferies Reiterates Hold Rating, Raises PT on Johnson & Johnson Following SOTP Analysis

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson JNJ, and raised the price target from $90.00 to $97.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of undervalued assets we have prepared a highly proprietary sum of the parts analysis for our coverage universe to find the best opportunities. As a result we have upgraded Bayer and Merck & Co. to Buy from Hold and Eli Lilly to Hold from U/P, though it remains our least preferred stock. Novartis and Abbott are now our Top European and US picks respectively.” Johnson & Johnson closed on Friday at $86.82.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferiesJeffrey Holford
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!